Cargando…

Preservation of neurocognitive function in the treatment of brain metastases

Neurocognitive function (NCF) deficits are common in patients with brain metastases, occurring in up to 90% of cases. NCF deficits may be caused by tumor-related factors and/or treatment for the metastasis, including surgery, radiation therapy, chemotherapy, and immunotherapy. In recent years, strat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parsons, Michael W, Peters, Katherine B, Floyd, Scott R, Brown, Paul, Wefel, Jeffrey S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633744/ https://www.ncbi.nlm.nih.gov/pubmed/34859237 http://dx.doi.org/10.1093/noajnl/vdab122

Ejemplares similares

SPCR-04 EFFECTS OF BRAIN METASTASES ON NEUROCOGNITIVE FUNCTION: BASELINE RESULTS OF A LONGITUDINAL TRIAL
por: Higazy, Randa, et al.
Publicado: (2022)

48. DEVELOPING TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL STEM CELLS AS AN ADJUVANT TREATMENT FOR RADIATION THERAPY OF BRAIN METASTASES
por: Mercer-Smith, Alison, et al.
Publicado: (2020)

RADI-09. Clinical factors associated with death after radiotherapy for brain metastases
por: Natesan, Divya, et al.
Publicado: (2021)

BSCI-05 REPURPOSING PROPOFOL FOR THE TREATMENT OF BRAIN METASTASES
por: Penning, Donald, et al.
Publicado: (2022)

TIPS-15 NEUROCOGNITIVE FUNCTION AND NEUROCOGNITIVE CONCERNS IN AN ONGOING PHASE III TRIAL OF PRE-OPERATIVE SRS VERSUS POST-OPERATIVE SRS FOR BRAIN METASTASES
por: Wefel, Jeffrey, et al.
Publicado: (2023)

MMAP-07 IMPACT OF SINGLE AND DUAL IMMUNE CHECKPOINT BLOCKADE ON RISK OF RADIATION NECROSIS AMONG PATIENTS WITH BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY
por: Vaios, Eugene, et al.
Publicado: (2022)

RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM)
por: Tomé, Wolfgang, et al.
Publicado: (2019)

Special issue: advances in the multimodality management of brain metastases and ongoing approaches to further improve their treatment
por: Zuccato, Jeffrey A, et al.
Publicado: (2021)

Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers
por: Brem, Steven, et al.
Publicado: (2013)

TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF A CLINICAL TRIAL
por: Kirkpatrick, John, et al.
Publicado: (2019)

OTHR-10. Diverse survival outcomes of HER2+ Breast Cancer Brain Metastases (BrCBM) presenting with isolated brain relapse compared to those with concurrent extracranial disease
por: Noteware, Laura, et al.
Publicado: (2021)

Advances in radiotherapy for brain metastases
por: Gondi, Vinai, et al.
Publicado: (2021)

MMAP-04 CYTOTOXIC, TUMOR-HOMING INDUCED NEURAL STEM CELLS AS AN ADJUVANT TO RADIATION IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER LEPTOMENINGEAL METASTASES
por: Mercer-Smith, Alison, et al.
Publicado: (2022)

MLTI-03. The relevance of the count of brain metastases for treatment and outcome in NSCLC
por: Reinecke, David, et al.
Publicado: (2021)

Emergent immunotherapy approaches for brain metastases
por: Wang, Jianbo, et al.
Publicado: (2021)

Surgical advances in the management of brain metastases
por: Ng, Patrick R, et al.
Publicado: (2021)

Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies
por: Myall, Nathaniel J, et al.
Publicado: (2021)

OTHR-14. An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM)
por: Kennedy, Lucy Boyce, et al.
Publicado: (2021)

MLTI-05. Adjuvant re-irradiation improves local control of surgically resected recurrent brain metastases
por: Wilcox, Jessica, et al.
Publicado: (2021)

30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
por: Mehta, Minesh P, et al.
Publicado: (2020)

Advances in the management of breast cancer brain metastases
por: Sammons, Sarah, et al.
Publicado: (2021)

Laser interstitial thermal therapy for brain metastases
por: Srinivasan, Ethan S, et al.
Publicado: (2021)

The microenvironment of brain metastases from solid tumors
por: Srinivasan, Ethan S, et al.
Publicado: (2021)

OTHR-01. Unmet clinical needs in patients with brain metastases in the current treatment era
por: Eggen, Annemarie C, et al.
Publicado: (2021)

LOCL-04 SAFETY AND FEASIBILITY OF RHENIUM-186 NANOLIPOSOME (186RNL) IN LEPTOMENINGEAL METASTASES [LM] PHASE 1/2A DOSE ESCALATION TRIAL
por: Brenner, Andrew, et al.
Publicado: (2022)

32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES
por: Galldiks, Norbert, et al.
Publicado: (2020)

MMAP-09 CHARACTERISTICS CORRELATING WITH SURVIVAL IN PATIENTS TREATED FOR LARGE BRAIN METASTASES
por: Gutierrez-Valencia, Enrique, et al.
Publicado: (2022)

SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION
por: Correa, Denise, et al.
Publicado: (2022)

RADI-06. Gamma knife surgery for brain stem metastases
por: Tan, Choo Heng, et al.
Publicado: (2021)

71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES
por: Mamatjan, Yasin, et al.
Publicado: (2020)

12. OUTCOMES AFTER SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE AGE OF CHECKPOINT INHIBITOR TREATMENT
por: Morshed, Ramin, et al.
Publicado: (2020)

LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Guerra-Garcia, Maria, et al.
Publicado: (2021)

RADI-01. Cystic brain metastases managed with reservoir placement and stereotactic radiosurgery
por: Park, David, et al.
Publicado: (2021)

SURG-13. Multiplicity does not affect outcomes in patients with surgically treated brain metastases
por: Yang, Kaiyun, et al.
Publicado: (2021)

Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles
por: Steindl, Ariane, et al.
Publicado: (2021)

Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases
por: Blethen, Kathryn E, et al.
Publicado: (2021)

65. INVASIVE HISTOPATHOLOGY DRIVES POOR OUTCOMES IN SURGICALLY RESECTED BRAIN METASTASES
por: Dankner, Matthew, et al.
Publicado: (2020)

13. MANAGEMENT OF BRAIN METASTASES FROM SMALL CELL LUNG CANCER USING SRS
por: Koffler, Daniel, et al.
Publicado: (2020)

43. DELAYS IN ADJUVANT STEREOTACTIC RADIOSURGERY REDUCE LOCAL CONTROL FOR RESECTED BRAIN METASTASES
por: Roth O’Brien, Diana, et al.
Publicado: (2020)

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment
por: Tallet, Agnes V, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nru5rn6r1qm6a3i2pbnvo9flle